Parabilis Medicines
PublicParabilis Medicines is now publicly traded
The data on this page reflects Parabilis Medicines's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Jun 9, 2026
Last Round
Series F
Jan 8, 2026
Total Funding Raised
$1.57B
Company Overview
The recorded funding history for Parabilis Medicines includes a Series F round in January 2026. Parabilis Medicines has raised $1.57B.
Parabilis Medicines is a clinical-stage biopharmaceutical company that develops stabilized helical peptide therapeutics, known as Helicons, to target undruggable protein-protein interactions in oncology.
AI Layer
Application
Parabilis Medicines Comparables
Compare Parabilis Medicines with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| WntRx Pharmaceuticals | 77% | |
| Sapience Therapeutics | 77% | |
| Circle Pharma | 76% |
For institutional investors. Book with your work email.
Parabilis Medicines Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Jun 9, 2026 | ||||
| Series F | Jan 8, 2026 | ||||
| Series E | Mar 1, 2024 | ||||
| Series D | Nov 21, 2022 | ||||
| Series C | Mar 1, 2021 | ||||
Series B | May 16, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Parabilis Medicines Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Soleus Capital | Series F |
| Janus Henderson Group | Series F |
| Horizons Ventures | Series B |
| Boyu Capital | Series B |
| RA Capital Management | Series E, Series F |
| Farallon Capital Management | Series F, Series C, Series E, Series D |
| Sixty Degree Capital | Series F, Series E |
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- has_revenueNov 12, 2026
Parabilis Medicines reports Q3 '26 revenue of $2.11M.
- has_lossNov 12, 2026
Parabilis Medicines, a clinical-stage pharmaceutical company, reports a $44.5M loss in its third quarter in Massachusetts on Nov 12th '26.
- attends_eventOct 24, 2026
Parabilis Medicines presents updated clinical data for zolucatetide in patients with desmoid tumors at the European Society for Medical Oncology (ESMO) Congress 2026 in Spain from Oct 23rd-27th '26.
- attends_eventOct 19, 2026
Parabilis Medicines presents updated clinical data for zolucatetide in patients with desmoid tumors at ESMO Congress 2026 in Spain in Oct '26.
- has_revenueSep 14, 2026
Parabilis Medicines generates $150K in quarterly revenue alongside a $2.32-per-share loss.
For institutional investors. Book with your work email.
Parabilis Medicines Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.